Pegylated liposomal doxorubicin (Caelyx™) in recurrent ovarian cancer

This publication has 16 references indexed in Scilit:

• Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin
  Cancer, 2001
• Phase 2 Trial of Liposomal Doxorubicin (40 mg/m2) in Platinum/Paclitaxel-Refractory Ovarian and Fallopian Tube Cancers and Primary Carcinoma of the Peritoneum
  Gynecologic Oncology, 2000
• Phase II Study of Liposomal Doxorubicin in Advanced Gynecologic Cancers
  Gynecologic Oncology, 2000
• ICON2: randomised trial of single-agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer
  The Lancet, 1998
• Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: A multivariate analysis of 704 patients
  Annals of Oncology, 1997
• Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.
  Journal of Clinical Oncology, 1997
• The importance of dose and schedule in cancer chemotherapy
  Anti-Cancer Drugs, 1995
• Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
  Journal of Clinical Oncology, 1991
• Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds
  Gynecologic Oncology, 1990
• Response of patients in phase II studies of chemotherapy in ovarian cancer: implications for patient treatment and the design of phase II trials
  British Journal of Cancer, 1989